Delving into the Latest Updates on Seinda Pharmaceutical Corp. with Synapse

Overview

Tags

Eye Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Immune System Diseases	1

Top 5 Drug Type	Count

Chemical drugs	3
Small molecule drug	2

This is a phase 2, multi-center, double-masked, randomized, vehicle-controlled, dose-response, parallel-group study designed to evaluate the safety and tolerability and ocular efficacy of SY-201 Ophthalmic Solution versus vehicle over a 60-day treatment period in subjects with dry eye disease (DED).

Start Date25 Jul 2022

Sponsor / Collaborator

Seinda Pharmaceutical Corp.

100 Clinical Results associated with Seinda Pharmaceutical Corp.

Login to view more data

0 Patents (Medical) associated with Seinda Pharmaceutical Corp.

Login to view more data

100 Deals associated with Seinda Pharmaceutical Corp.

Login to view more data

100 Translational Medicine associated with Seinda Pharmaceutical Corp.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 15 Jun 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

3

Preclinical

Phase 2

1

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

SY-201	Dry Eye Syndromes More	Phase 2
SY-101	Myopia More	Preclinical
SY-301	Presbyopia More	Preclinical
SY-401	Retinal Diseases More	Discovery
SY-116	Keratitis More	Discontinued